FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to pharmacogenetics, clinical pharmacology, and can be used for dose selection levomepromazine in patients with psychotic symptoms. For this purpose, based on the results of genotyping using polymorphic markers of CYP2D6 genes, the resultant rate change is calculated biotransformation of levomepromazine (parameter P) by formula:
,
where: Wg is the number of CYP2D6 gene polymorphisms (main pathway biotransformation of levomepromazine); Ai – change of speed biotransformation of levomepromazine, depending on the genotype for each polymorphic marker of the CYP2D6 gene. If change is defined as speed deviation biotransformation of levomepromazine by 50 % and higher, replacement of the drug is recommended. At change of speed defined as deceleration biotransformation of levomepromazine less than 50 % is recommended to reduce dose. If change is defined as speed acceleration biotransformation of levomepromazine more than by 50 %, dose increase is recommended.
EFFECT: use of this method enables individual dose selection levomepromazine, determining degree of manifestation of deviation of its speed biotransformation depending on the genotype for each polymorphic marker of the CYP2D6 gene.
1 cl, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREDICTION OF EVALUATION OF EFFICACY OF DAPOXETINE THERAPY FOR TREATING DISORDERS ACCOMPANIED BY DEVELOPMENT OF DEPRESSIVE SYMPTOMS | 2019 |
|
RU2717245C1 |
METHOD OF ESTIMATING THE EFFECTIVENESS OF MIRTAZAPINE THERAPY FOR TREATING DISORDERS ACCOMPANIED BY DEVELOPMENT OF DEPRESSIVE SYMPTOMS | 2019 |
|
RU2734347C1 |
METHOD OF ESTIMATING THE EFFICACY OF FLUVOXAMINE THERAPY FOR TREATING DISORDERS ACCOMPANIED BY DEVELOPMENT OF DEPRESSIVE SYMPTOMS | 2019 |
|
RU2722834C1 |
METHOD OF ESTIMATING THE EFFICACY OF THE PROMAZINE THERAPY FOR TREATING DISORDERS ACCOMPANYING DEVELOPMENT OF PSYCHOTIC SYMPTOMS | 2018 |
|
RU2695659C1 |
METHOD FOR PREDICTION OF CHLORPROMAZINE THERAPY EFFECTIVENESS EVALUATION FOR TREATING DISORDERS ACCOMPANYING DEVELOPMENT OF PSYCHOTIC SYMPTOMS | 2018 |
|
RU2695658C1 |
METHOD OF ESTIMATING THE EFFICACY OF FLUPHENAZINE THERAPY FOR TREATING DISORDERS ACCOMPANYING DEVELOPMENT OF PSYCHOTIC SYMPTOMS | 2018 |
|
RU2695821C1 |
METHOD OF ESTIMATING THE CLINICAL EFFECTIVENESS OF TRIFLUOPERAZINE FOR TREATING DISORDERS ACCOMPANYING DEVELOPING PSYCHOTIC SYMPTOMS | 2018 |
|
RU2695820C1 |
METHOD FOR PREDICTING THE EFFICIENCY OF HALOPERIDOL THERAPY FOR THE TREATMENT OF DISORDERS ACCOMPANIED BY THE DEVELOPMENT OF PSYCHOTIC SYMPTOMS | 2017 |
|
RU2643944C1 |
METHOD FOR IMPROVING DRUG USE SAFETY IN TREATING PATIENTS WITH ALCOHOL WITHDRAWAL SYNDROME | 2018 |
|
RU2690522C1 |
METHOD FOR CHOOSING THE STARTING SCHEME OF POSTOPERATIVE ANESTHESIA IN PATIENTS AFTER VIDEOLAPAROSCOPIC CHOLECYSTECTOMY | 2021 |
|
RU2779003C1 |
Authors
Dates
2019-07-25—Published
2018-09-28—Filed